| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from rat) |
| Target | IL6 |
| Clinical data | |
| Trade names | Artlegia |
| Routes of administration | Subcutaneous |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 31 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Molar mass | 146000 Da |
  (what is this?) (verify) | |
Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6). IL-6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases. Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor.[1] Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex.[2] Olokizumab was developed by R-Pharm group, and was launched in 2020.[3]
- ^ Cite error: The named reference
pmid36792848was invoked but never defined (see the help page). - ^ Nasonov EL, Feist E (2022-11-10). "Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6)" [The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)]. Rheumatology Science and Practice (in Russian). 60 (5): 505–518. doi:10.47360/1995-4484-2022-505-518. ISSN 1995-4492.
- ^ "Государственный реестр лекарственных средств" [State register of medicinal products]. grls.rosminzdrav.ru (in Russian). Retrieved 2024-04-01.